| Dr Christopher Gregory Przybycin, MD | |
|
9500 Euclid Ave, L25, Cleveland, OH 44195-0001 | |
| (216) 444-8421 | |
| (216) 445-3707 |
| Full Name | Dr Christopher Gregory Przybycin |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 21 Years |
| Location | 9500 Euclid Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073730248 | NPI | - | NPPES |
| 018316400 | Medicaid | MD |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Hillcrest Hospital | Mayfield heights, OH | Hospital |
| Fairview Hospital | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
A team of researchers at Children's Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) further bridged the gap between genomic information and clinical outcome data by systematically linking genetic information with electronic medical records, focusing on how genetic neurological disorders in children develop over time.
A Center for Global Development (CGD) report released Tuesday details factors leading to increased drug resistance worldwide, including drug distribution programs in developing countries, Reuters reports.
Everyman scientists at The Institute of Cancer Research have established an initiative to promote vital research for the development and clinical testing of new drugs for the treatment of prostate cancer. This announcement coincides with the launch of The Institute's Everyman Male Cancer Awareness Month which runs throughout June.
The regulation is likely to trigger "stiff resistance" from governors and some members of Congress who fear it will undermine the ability of states to control Medicaid spending.
INVISTA Technologies S.à r.l. and Arzeda Corp. announce a collaboration for the development of new technologies to enable novel bio-derived processes.
› Verified 3 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
A team of researchers at Children's Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) further bridged the gap between genomic information and clinical outcome data by systematically linking genetic information with electronic medical records, focusing on how genetic neurological disorders in children develop over time.
A Center for Global Development (CGD) report released Tuesday details factors leading to increased drug resistance worldwide, including drug distribution programs in developing countries, Reuters reports.
Everyman scientists at The Institute of Cancer Research have established an initiative to promote vital research for the development and clinical testing of new drugs for the treatment of prostate cancer. This announcement coincides with the launch of The Institute's Everyman Male Cancer Awareness Month which runs throughout June.
The regulation is likely to trigger "stiff resistance" from governors and some members of Congress who fear it will undermine the ability of states to control Medicaid spending.
INVISTA Technologies S.à r.l. and Arzeda Corp. announce a collaboration for the development of new technologies to enable novel bio-derived processes.
› Verified 3 days ago
| Entity Name | Wooster Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033135009 PECOS PAC ID: 6800708124 Enrollment ID: O20031211000578 |
News Archive
A team of researchers at Children's Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) further bridged the gap between genomic information and clinical outcome data by systematically linking genetic information with electronic medical records, focusing on how genetic neurological disorders in children develop over time.
A Center for Global Development (CGD) report released Tuesday details factors leading to increased drug resistance worldwide, including drug distribution programs in developing countries, Reuters reports.
Everyman scientists at The Institute of Cancer Research have established an initiative to promote vital research for the development and clinical testing of new drugs for the treatment of prostate cancer. This announcement coincides with the launch of The Institute's Everyman Male Cancer Awareness Month which runs throughout June.
The regulation is likely to trigger "stiff resistance" from governors and some members of Congress who fear it will undermine the ability of states to control Medicaid spending.
INVISTA Technologies S.à r.l. and Arzeda Corp. announce a collaboration for the development of new technologies to enable novel bio-derived processes.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Gregory Przybycin, MD 9500 Euclid Ave, L25, Cleveland, OH 44195-0001 Ph: (216) 444-8421 | Dr Christopher Gregory Przybycin, MD 9500 Euclid Ave, L25, Cleveland, OH 44195-0001 Ph: (216) 444-8421 |
News Archive
A team of researchers at Children's Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) further bridged the gap between genomic information and clinical outcome data by systematically linking genetic information with electronic medical records, focusing on how genetic neurological disorders in children develop over time.
A Center for Global Development (CGD) report released Tuesday details factors leading to increased drug resistance worldwide, including drug distribution programs in developing countries, Reuters reports.
Everyman scientists at The Institute of Cancer Research have established an initiative to promote vital research for the development and clinical testing of new drugs for the treatment of prostate cancer. This announcement coincides with the launch of The Institute's Everyman Male Cancer Awareness Month which runs throughout June.
The regulation is likely to trigger "stiff resistance" from governors and some members of Congress who fear it will undermine the ability of states to control Medicaid spending.
INVISTA Technologies S.à r.l. and Arzeda Corp. announce a collaboration for the development of new technologies to enable novel bio-derived processes.
› Verified 3 days ago
Dr. Mary Katherine Allen-proctor, MD Pathology Medicare: May Accept Medicare Assignments Practice Location: 9500 Euclid Ave # Na-23, Cleveland, OH 44195 Phone: 216-444-2200 | |
Lan Zhou, MD Pathology Medicare: Medicare Enrolled Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7494 Fax: 440-449-1555 | |
Dr. Sarah Ann White, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave, Rm 211b, Ms Pth 5077, Cleveland, OH 44106 Phone: 216-286-6590 | |
Dr. Ana Lucia Ruano Mendez, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave # L25, Cleveland, OH 44195 Phone: 216-444-6781 | |
Akeesha A Shah, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, L25, Cleveland, OH 44193 Phone: 216-636-9407 | |
Michael R Jacobs, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7494 Fax: 216-286-6341 | |
Priscilla I Figueroa, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 800-223-2273 |